Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Monthly Archives: January 2013
Hyping the Economic Impact of the California Stem Cell Agency
Posted: January 31, 2013 at 9:03 pm
The $3 billion California stem cell agency today served up a warmed-over version of a study that would have the
public believe that the research program has had a major economic
impact on the state.
The latest study was prepared last
August by a firm that was hired under an RFP in 2010 that said it must execute "a vibrant and aggressive strategy to support the goals and initiatives of CIRM.”
August by a firm that was hired under an RFP in 2010 that said it must execute "a vibrant and aggressive strategy to support the goals and initiatives of CIRM.”
The agency paid $300,000 for the
original study but contends the report is “independent” of CIRM.
original study but contends the report is “independent” of CIRM.
According to the CIRM press release
today, the latest version of the study by Jose Alberro of the
Berkeley Research Group claims creation of 38,000 “job years” and
$286 million in “new tax revenue” from the award of $1.5 billion. Those awards actually cost something in the neighborhood of $3 billion, given that state taxpayers must pay interest the borrowed funds that finance the agency.
today, the latest version of the study by Jose Alberro of the
Berkeley Research Group claims creation of 38,000 “job years” and
$286 million in “new tax revenue” from the award of $1.5 billion. Those awards actually cost something in the neighborhood of $3 billion, given that state taxpayers must pay interest the borrowed funds that finance the agency.
The Institute of Medicine's recent
blue-ribbon report on the stem cell agency carried remarkably different
information than the economic figures reported today. The institute's study was also financed by CIRM but at a cost of
$700,000. The report said,
blue-ribbon report on the stem cell agency carried remarkably different
information than the economic figures reported today. The institute's study was also financed by CIRM but at a cost of
$700,000. The report said,
“In the short term, CIRM’s
expenditures are supporting approximately 3,400 jobs and their
innovative efforts have also attracted substantial additional private
and institutional resources to this research arena in California
CIRM’s long-term impact on such critical aspects of the California
economy as state tax revenues and health care costs beyond the
shorter-term and temporary impact of its direct expenditures cannot
be reliably estimated at this point in CIRM’s history."
Here is what the California Stem Cell Report wrote in 2011 when the first study was released:
“No doubt exists that the stem cell
spending has had a beneficial economic impact. But whether it has had
a 'significant' impact on the California economy is in the eye of the
beholder. The state's economy runs to something like $1.7 trillion a
year. If California were a nation, it would rank among one of the
larger economies in the world. The workforce totals around 18
million, making 25,000 jobs statistically less than a hiccup. Keep in
mind as well that CIRM, until 2009, paid the interest on its
borrowing with more borrowed funds, all of which adds to the total
cost of the borrowing, which is about $3 billion on top of the $3
billion CIRM is handing out.”
By ballyhooing economic impact reports
the stem cell agency would seem to be inviting assessment of its
efforts as an industrial development enterprise, which involve
criteria significantly different than that of a research enterprise.
A few years ago, we asked the agency's then Chairman Robert Klein
whether he wanted to have CIRM assessed as industrial development
effort. His quick response was a very emphatic no. Klein nonetheless
frequently touted the figures produced under the contract with the
agency.
the stem cell agency would seem to be inviting assessment of its
efforts as an industrial development enterprise, which involve
criteria significantly different than that of a research enterprise.
A few years ago, we asked the agency's then Chairman Robert Klein
whether he wanted to have CIRM assessed as industrial development
effort. His quick response was a very emphatic no. Klein nonetheless
frequently touted the figures produced under the contract with the
agency.
The latest figures are undoubtedly
likely to be cited as the agency begins a road trip around the state
to meet with newspaper editorial boards to trumpet CIRM's reponse to
the Institute of Medicine study.
likely to be cited as the agency begins a road trip around the state
to meet with newspaper editorial boards to trumpet CIRM's reponse to
the Institute of Medicine study.
See below for a full copy of the
report. We have asked CIRM for a copy of the contract with the group
that prepared it. We will carry it when we receive it.
report. We have asked CIRM for a copy of the contract with the group
that prepared it. We will carry it when we receive it.
Posted in Stem Cells, Stem Cell Therapy
Comments Off on Hyping the Economic Impact of the California Stem Cell Agency
Potent growth-inhibitory effect of a dual cancer-specific oncolytic adenovirus expressing apoptin on prostate carcinoma.
Posted: January 31, 2013 at 7:30 am
Potent growth-inhibitory effect of a dual cancer-specific oncolytic adenovirus expressing apoptin on prostate carcinoma.
Int J Oncol. 2013 Mar;42(3):1052-60
Authors: Zhang M, Wang J, Li C, Hu N, Wang K, Ji H, He D, Quan C, Li X, Jin N, Li Y
Abstract
Apoptin is a chicken anemia virus-derived, p53-independent, bcl-2-insensitive apoptotic protein with the ability to specifically induce apoptosis in various human tumor cells, but not in normal cells. To explore the use of apoptin in tumor gene therapy, we assessed a recombinant adenovirus expressing the apoptin protein (Ad-hTERTp-E1a-Apoptin) in order to determine its lethal and growth-inhibitory effects on PC-3 and RM-1 cells in vitro and its antitumor effect on solid tumors in vivo....
MedWorm Sponsor Message: Find the best Christmas presents and January Sales in the UK with this simple shopping directory.
Posted in Gene therapy
Comments Off on Potent growth-inhibitory effect of a dual cancer-specific oncolytic adenovirus expressing apoptin on prostate carcinoma.
Timothy Ray Brown, the Berlin Patient, Speaks to the ACTG (Full Version) – Video
Posted: January 31, 2013 at 4:48 am
Timothy Ray Brown, the Berlin Patient, Speaks to the ACTG (Full Version)
Timothy Ray Brown, also known as the Berlin Patient, shares how living with HIV and then being diagnosed with leukemia led his German oncologist to try an innovative treatment using stem cells from a donor with a mutation that makes cells immune to HIV. Mr. Brown spoke at the AIDS Clinical Trials Group Network #39;s University of California at San Diego AntiViral Research Center site #39;s Community Advisory Board meeting on Nov. 12, 2012. He is the only known cured case of HIV in the world. Mr. Brown also shares his hope for the future of HIV/AIDS research. Our previous cut of this video showed highlights from this presentation. This video features Mr. Brown #39;s talk in its entirety.
By: ACTGNetwork
Here is the original post:
Timothy Ray Brown, the Berlin Patient, Speaks to the ACTG (Full Version) - Video
Posted in Stem Cell Videos
Comments Off on Timothy Ray Brown, the Berlin Patient, Speaks to the ACTG (Full Version) – Video
epidermal stem cells – Video
Posted: January 31, 2013 at 4:48 am
Posted in Stem Cell Videos
Comments Off on epidermal stem cells – Video
Biotech Showcase 2012_Stem Cells, Inc. – Video
Posted: January 31, 2013 at 4:48 am
Biotech Showcase 2012_Stem Cells, Inc.
StemCells, Inc. is applying its scientific and industry leadership in stem cell biology to discover, develop and commercialize breakthrough therapeutics and enabling tools and technologies for use in stem cell-based research and drug discovery. http://www.stemcellsinc.com View Stem Cells Inc. #39;s Alliance for Regenerative Medicine member profile at alliancerm.org
By: AllianceRegenMed
Original post:
Biotech Showcase 2012_Stem Cells, Inc. - Video
Posted in Stem Cell Videos
Comments Off on Biotech Showcase 2012_Stem Cells, Inc. – Video
Biotech Showcase 2012_NeuralStem – Video
Posted: January 31, 2013 at 4:48 am
Biotech Showcase 2012_NeuralStem
Neuralstem #39;s patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. In August 2012, Neuralstem completed the final surgery of an FDA-approved Phase I NSI-566 safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig #39;s disease. The trial is the first FDA-approved neural stem cell trial to treat ALS and concludes six months after that surgery. Neuralstem #39;s lead cell therapy candidate NSI-566 has been awarded orphan drug designation by the FDA for the treatment of ALS. http://www.neuralstem.com
By: AllianceRegenMed
See more here:
Biotech Showcase 2012_NeuralStem - Video
Posted in Stem Cell Videos
Comments Off on Biotech Showcase 2012_NeuralStem – Video
Biotech Showcase 2012_AlloCure – Video
Posted: January 31, 2013 at 4:48 am
Biotech Showcase 2012_AlloCure
AlloCure, Inc. is a pioneer in the development of cell therapies for the treatment of kidney disease and is a leader in the acute kidney injury field. The company #39;s proprietary technology enables the isolation and expansion of mesenchymal stem cells (MSC), obtained via conventional bone marrow donation, which can then be administered off-the-shelf to any patient in need without requiring tissue matching or immunosuppressants. The company #39;s most advanced program, AC607, targeting acute kidney injury, is entering phase 2 clinical development and represents the first cell therapy to treat this life threatening condition. http://www.allocure.com View AlloCure #39;s Alliance for Regenerative Medicine member profile at alliancerm.org
By: AllianceRegenMed
Read more:
Biotech Showcase 2012_AlloCure - Video
Posted in Stem Cell Videos
Comments Off on Biotech Showcase 2012_AlloCure – Video
embryonic stem cells 2 – Video
Posted: January 31, 2013 at 4:48 am
embryonic stem cells 2
Video featuring a colony of embryonic stem cells (ESCs). For more info on ESCs check out this article http://www.stemcellsfreak.com from Stem Cells Freak.
By: Nikos Korompos
See more here:
embryonic stem cells 2 - Video
Posted in Stem Cell Videos
Comments Off on embryonic stem cells 2 – Video
Wheelchair style – Plastic Surgeon Doctor Discussion For Bursitis
Posted: January 31, 2013 at 4:48 am
Wheelchair style - Plastic Surgeon Doctor Discussion For Bursitis Stem Cells - L1 injury 1-29-13
Audio from my appointment today with Plastic Surgeon. The Doctor gave me 2 options today. Surgery or see if holes close up within 2 months. I #39;ve gained 15 lbs in ~2 months, now i weigh ~150lbs. New skin could be grown from my Stem Cells, but New skin would be very thin weak, scarring very easily. So far this type of New Skin is only used on severly burned individuals, with no extra skin available to graft from their body. I #39;m paraplegic(20 years in a wheelchair) with Website wheelchairstyl.com, https wheelchairstyl.com, http twitter.com .Many of the things i do are either done wrong or incorrectly. Doing things the incorrect way is probably what made me paraplegic in the first place. Even though they are probably not correct, i hope my video gives you an idea you might possibly be able to do safely correctly yourself. Follow these videos at your own risk 🙂
By: d72466fly
See original here:
Wheelchair style - Plastic Surgeon Doctor Discussion For Bursitis
Posted in Stem Cell Videos
Comments Off on Wheelchair style – Plastic Surgeon Doctor Discussion For Bursitis
FREE sample of 12 Hour MBA in Stem Cells – Terrapinn Training – Video
Posted: January 31, 2013 at 4:48 am
FREE sample of 12 Hour MBA in Stem Cells - Terrapinn Training
http://www.12hourmba.com 12 Hour MBA in Stem Cells The 12 Hour MBA in Stem Cells is an introductory level course designed to bridge gaps in your knowledge. It is most useful to new entrants, senior managers needing a big picture refresher, professional advisors and suppliers to the industry. We make it all easy -- leading you through the dynamics of stem cells, the main business drivers, giving you precious insight into where the money is made, stem cell development, commercialisation and ethics. In less than 12 hours you #39;ll: - Understand stem cells from bench to bedside - Discover where the money is made with stem cells - Understand risk and project management techniques for stem cells - Explore practices for stem cell product commercialisation - Learn about regulations, the government and the impact they can have - Consider the ethics of stem cells - Discover what the future holds for stem cells For more information, contact us at: http://www.terrapinntraining.com/contact-us.aspx
By: TerrapinnTraining
Read more:
FREE sample of 12 Hour MBA in Stem Cells - Terrapinn Training - Video
Posted in Stem Cell Videos
Comments Off on FREE sample of 12 Hour MBA in Stem Cells – Terrapinn Training – Video